Article

Now: Neoadjuvant Olaparib window trial in patients with newly diagnosed BRCA mutant ovarian cancer (LBA 1)

2023-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6270dae6-cef9-56a4-a4b9-5e676a9d8b17
DOI: 10.1016/j.ygyno.2023.06.467

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Now: Neoadjuvant Olaparib window trial in patients with newly diagnosed BRCA mutant ovarian cancer (LBA 1)DOI 10.1016/j.ygyno.2023.06.467Read

Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohortSemantic proximity Read

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)Semantic proximity Read

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)Semantic proximity Read

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read

First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter studySemantic proximity Read

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)Semantic proximity Read

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancerSemantic proximity Read

Olaparib and advanced ovarian cancer: Summary of the past and looking into the futureSemantic proximity Read

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read

FDA approves olaparib for germline BRCA-mutated metastatic breast cancerSemantic proximity Read

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)Semantic proximity Read

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerSemantic proximity Read